Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)
Year: 2008
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: R. G. Bociek, J. Kuruvilla, B. Pro, A. Wedgwood, Z. Li, M. Drouin, T. Patterson, R. Ward, R. E. Martell, A. Younes
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2529676265